Literature DB >> 8990142

Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate (Kayexalate) in sorbitol: an underrecognized condition.

A Rashid1, S R Hamilton.   

Abstract

Sodium polystyrene sulfonate (Kayexalate) in sorbitol given as an enema or orally to treat hyperkalemia has been reported to induce intestinal necrosis in uremic patients. We studied the clinical and pathologic features of 15 patients in whom Kayexalate crystals were observed in specimens from gastrointestinal surgical resections (n = 9) or endoscopic biopsies (n = 7). Oral or nasogastric tube administration of Kayexalate in sorbitol was documented in 10 patients. Among 12 patients with colorectal specimens, necrosis was observed in nine patients (75%), represented by seven of eight surgical resection specimens and three of five endoscopic biopsy specimens. No other cause of colorectal necrosis apart from Kayexalate in sorbitol was apparent in seven patients, and four also had necrosis of the small intestine. Four patients with colonic necrosis in their initial resection specimen developed progressive necrosis of the small intestine or rectum, and five patients (56%) had fatal outcome within 1 day to 6 weeks. Kayexalate crystals were observed in upper gastrointestinal tract specimens from four patients, including one with hemorrhagic gastritis. Our findings provide additional evidence that Kayexalate in sorbitol administered orally or by nasogastric tube can produce necrosis in the gastrointestinal tract.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8990142     DOI: 10.1097/00000478-199701000-00007

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  33 in total

Review 1.  Sumatriptan-associated ischemic colitis: case report and review of the literature and FAERS.

Authors:  Thuc Quyen Nguyen; James H Lewis
Journal:  Drug Saf       Date:  2014-02       Impact factor: 5.606

2.  Vancomycin-resistant Enterococcus faecium bacteraemia as a complication of Kayexalate (sodium polystyrene sulfonate, SPS) in sorbitol-induced ischaemic colitis.

Authors:  Roberto Christian Cerrud-Rodriguez; Diego Alcaraz-Alvarez; Brian Bobby Chiong; Abdurhman Ahmed
Journal:  BMJ Case Rep       Date:  2017-11-09

Review 3.  Hypokalaemia and hyperkalaemia.

Authors:  A Rastegar; M Soleimani; A Rastergar
Journal:  Postgrad Med J       Date:  2001-12       Impact factor: 2.401

4.  The use of histological techniques for the demonstration of ion exchange resins.

Authors:  A J Chaplin
Journal:  J Clin Pathol       Date:  1999-10       Impact factor: 3.411

5.  OsmoPrep-associated Gastritis: A Histopathologic Mimic of Iron Pill Gastritis and Mucosal Calcinosis.

Authors:  Karen Matsukuma; Dorina Gui; Kristin A Olson; Sooraj Tejaswi; Erica F Clayton; Anne Thai
Journal:  Am J Surg Pathol       Date:  2016-11       Impact factor: 6.394

6.  Colonic necrosis due to sodium polystyrene sulfate (Kayexalate).

Authors:  Andrew S Bomback; John T Woosley; Abhijit V Kshirsagar
Journal:  Am J Emerg Med       Date:  2009-07       Impact factor: 2.469

7.  Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol.

Authors:  C E McGowan; S Saha; G Chu; M B Resnick; S F Moss
Journal:  South Med J       Date:  2009-05       Impact factor: 0.954

8.  Ileocolic perforation secondary to sodium polystyrene sulfonate in sorbitol use: a case report.

Authors:  Vincent Trottier; Sébastian Drolet; Mohib W Morcos
Journal:  Can J Gastroenterol       Date:  2009-10       Impact factor: 3.522

9.  Colitis induced by sodium polystyrene sulfonate in sorbitol: A report of six cases.

Authors:  Sheba S K Jacob; Ashok Parameswaran; Sarojini Ashok Parameswaran; Ubal Dhus
Journal:  Indian J Gastroenterol       Date:  2016-04-01

10.  Colonic mucosal necrosis following administration of calcium polystryrene sulfonate (Kalimate) in a uremic patient.

Authors:  Mee Joo; Won Ki Bae; Nam Hoon Kim; Seong Rok Han
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.